Prescribing information

 

    _

EXJADE offers simple and convenient dosing for your patients compared with previous formulations.1,2

Transfusional iron overload in MDS, SCD and thalassaemia

EXJADE FCTs demonstrate higher bioavailability compared to the EXJADE DTs formulation. In case of switching from DTs to FCTs, the dose of the FCTs should be 30% lower than the dose of the DTs, rounded to the nearest whole tablet.

Starting dose:1

  • Recommended initial daily dose: 14 mg/kg/day
  • EXJADE can also be initiated at either 7 mg/kg/day or 21 mg/kg/day, depending on transfusion regimens and therapeutic goals

Recommended doses for transfusional iron overload1

Table showing the recommended doses of EXJADE for transfusional iron overload

Dose adjustments1

  • It is recommended that serum ferritin is monitored every month
  • If necessary, the dose of EXJADE may be adjusted every 3–6 months based on trends in serum ferritin
  • Dose adjustments may be made in steps of 3.5–7 mg/kg/day and should be tailored to the individual patient’s response and therapeutic goals

Adjustments based on LIC or serum ferritin1*

Table showing the recommended EXJADE dose adjustments based on LIC or serum ferritin

  • Dose adjustments may be made in steps of 3.5–7 mg/kg/day and should be tailored to the individual patient’s response and therapeutic goals

 

*LIC is the preferred method for iron overload determination.

Abbreviations: DT, dispersible tablet; FCT, film-coated tablet; ICT, iron chelation therapy; LIC, liver iron concentration; MDS, myelodysplastic syndromes; pRBC, packed red blood cells; SCD, sickle cell disease.

References

  1. EXJADE® film-coated tablets summary of product characteristics.
  2. Taher A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, Phase II ECLIPSE study. Am J Hematol 2017;92(5):420–428. 
HCP20-C005j June 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]